137 related articles for article (PubMed ID: 29051061)
1. Precise laser poration to control drug delivery into and through human nail.
Vanstone S; Cordery SF; Stone JM; Gordeev SN; Guy RH
J Control Release; 2017 Dec; 268():72-77. PubMed ID: 29051061
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of human nail poration by high-repetition-rate, femtosecond laser ablation.
Vanstone S; Stone JM; Gordeev SN; Guy RH
Drug Deliv Transl Res; 2019 Oct; 9(5):956-967. PubMed ID: 31016477
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of tioconazole ungual delivery: Combining nanocapsule formulation and nail poration approaches.
Flores FC; Chiu WS; Beck RCR; da Silva CB; Delgado-Charro MB
Int J Pharm; 2018 Jan; 535(1-2):237-244. PubMed ID: 29126904
[TBL] [Abstract][Full Text] [Related]
4. Drug delivery into microneedle-porated nails from nanoparticle reservoirs.
Chiu WS; Belsey NA; Garrett NL; Moger J; Price GJ; Delgado-Charro MB; Guy RH
J Control Release; 2015 Dec; 220(Pt A):98-106. PubMed ID: 26478016
[TBL] [Abstract][Full Text] [Related]
5. Microstructural alterations in the onychomycotic and psoriatic nail: Relevance in drug delivery.
Cutrín Gómez E; Anguiano Igea S; Delgado-Charro MB; Gómez Amoza JL; Otero Espinar FJ
Eur J Pharm Biopharm; 2018 Jul; 128():48-56. PubMed ID: 29673870
[TBL] [Abstract][Full Text] [Related]
6. Fractional CO
Ortner VK; Nguyen N; Brewer JR; Solovyeva V; Haedersdal M; Philipsen PA
Lasers Surg Med; 2022 Aug; 54(6):861-874. PubMed ID: 35451510
[TBL] [Abstract][Full Text] [Related]
7. Enhancing the nail permeability of topically applied drugs.
Murdan S
Expert Opin Drug Deliv; 2008 Nov; 5(11):1267-82. PubMed ID: 18976136
[TBL] [Abstract][Full Text] [Related]
8. Understanding the formidable nail barrier: A review of the nail microstructure, composition and diseases.
Baswan S; Kasting GB; Li SK; Wickett R; Adams B; Eurich S; Schamper R
Mycoses; 2017 May; 60(5):284-295. PubMed ID: 28098391
[TBL] [Abstract][Full Text] [Related]
9. Femtosecond pulsed laser ablation to enhance drug delivery across the skin.
Garvie-Cook H; Stone JM; Yu F; Guy RH; Gordeev SN
J Biophotonics; 2016 Jan; 9(1-2):144-54. PubMed ID: 26449289
[TBL] [Abstract][Full Text] [Related]
10. Controlled intra- and transdermal protein delivery using a minimally invasive Erbium:YAG fractional laser ablation technology.
Bachhav YG; Heinrich A; Kalia YN
Eur J Pharm Biopharm; 2013 Jun; 84(2):355-64. PubMed ID: 23207321
[TBL] [Abstract][Full Text] [Related]
11. An investigation of how fungal infection influences drug penetration through onychomycosis patient's nail plates.
McAuley WJ; Jones SA; Traynor MJ; Guesné S; Murdan S; Brown MB
Eur J Pharm Biopharm; 2016 May; 102():178-84. PubMed ID: 26969264
[TBL] [Abstract][Full Text] [Related]
12. Insights into drug delivery across the nail plate barrier.
Saner MV; Kulkarni AD; Pardeshi CV
J Drug Target; 2014 Nov; 22(9):769-89. PubMed ID: 24964054
[TBL] [Abstract][Full Text] [Related]
13. Ungual and transungual drug delivery.
Shivakumar HN; Juluri A; Desai BG; Murthy SN
Drug Dev Ind Pharm; 2012 Aug; 38(8):901-11. PubMed ID: 22149347
[TBL] [Abstract][Full Text] [Related]
14. Alteration of the diffusional barrier property of the nail leads to greater terbinafine drug loading and permeation.
Nair AB; Sammeta SM; Kim HD; Chakraborty B; Friden PM; Murthy SN
Int J Pharm; 2009 Jun; 375(1-2):22-7. PubMed ID: 19481686
[TBL] [Abstract][Full Text] [Related]
15. Transungual delivery of efinaconazole: its deposition in the nail of onychomycosis patients and in vitro fungicidal activity in human nails.
Sakamoto M; Sugimoto N; Kawabata H; Yamakawa E; Kodera N; Pillai R; Tatsumi Y
J Drugs Dermatol; 2014 Nov; 13(11):1388-92. PubMed ID: 25607707
[TBL] [Abstract][Full Text] [Related]
16. Enhancing transungual delivery and spreading of efinaconazole under the nail plate through a unique formulation approach.
Kircik LH
J Drugs Dermatol; 2014 Dec; 13(12):1457-61. PubMed ID: 25607788
[TBL] [Abstract][Full Text] [Related]
17. An investigation into keratinolytic enzymes to enhance ungual drug delivery.
Mohorcic M; Torkar A; Friedrich J; Kristl J; Murdan S
Int J Pharm; 2007 Mar; 332(1-2):196-201. PubMed ID: 17097244
[TBL] [Abstract][Full Text] [Related]
18. Human nail plate modifications induced by onychomycosis: implications for topical therapy.
Baraldi A; Jones SA; Guesné S; Traynor MJ; McAuley WJ; Brown MB; Murdan S
Pharm Res; 2015 May; 32(5):1626-33. PubMed ID: 25416028
[TBL] [Abstract][Full Text] [Related]
19. Design and development of a safer non-invasive transungual drug delivery system for topical treatment of onychomycosis.
Pal P; Thakur RS; Ray S; Mazumder B
Drug Dev Ind Pharm; 2015; 41(7):1095-9. PubMed ID: 24980914
[TBL] [Abstract][Full Text] [Related]
20. Matrix based system of isotretinoin as nail lacquer to enhance transungal delivery across human nail plate.
Joshi M; Sharma V; Pathak K
Int J Pharm; 2015 Jan; 478(1):268-277. PubMed ID: 25445993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
